产品
编 号：F013083
分子式：C17H15N3O2
分子量：293.32
分子式：C17H15N3O2
分子量：293.32
产品类型
规格
价格
是否有货
结构图
CAS No: 102771-26-6
产品详情
生物活性：
GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research.
体内研究：
GYKI 52466 (intraperitoneal injection; 1.76-13.2 mg/kg; once) treatment provides potent anticonvulsant protection against sound-induced seizures in DBA/2 mice.Animal Model:Male and female DBA/2 mice tested for sound-induced seizure responses
Dosage:1.76-13.2 mg/kg
Administration:Intraperitoneal injection; 1.76-13.2 mg/kg; once
Result:Observed Maximal anticonvulsant protection after the i.p. treatment (5-15 min ).
体外研究：
GYKI 52466 (0.3-100 μM) inhibits inward currents activated by AMPA and Kainate receptor in cultured rat hippocampal neurons.
GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research.
体内研究：
GYKI 52466 (intraperitoneal injection; 1.76-13.2 mg/kg; once) treatment provides potent anticonvulsant protection against sound-induced seizures in DBA/2 mice.Animal Model:Male and female DBA/2 mice tested for sound-induced seizure responses
Dosage:1.76-13.2 mg/kg
Administration:Intraperitoneal injection; 1.76-13.2 mg/kg; once
Result:Observed Maximal anticonvulsant protection after the i.p. treatment (5-15 min ).
体外研究：
GYKI 52466 (0.3-100 μM) inhibits inward currents activated by AMPA and Kainate receptor in cultured rat hippocampal neurons.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备